Infliximab accounts for substantial drug spending in the United States, and dose rounding has become a common practice at many facilities as a way to avoid wasting vials that have only been partially used. However, many institutions do not have standardized approaches to rounding doses, and because infliximab requires a weight-based dose, rounding becomes even more complex.
Infliximab accounts for substantial drug spending in the United States, and dose rounding has become a common practice at many facilities as a way to avoid wasting vials that have only been partially used. However, many institutions do not have standardized approaches to rounding doses, and because infliximab requires a weight-based dose, rounding becomes even more complex.
A research team from the Englewood Hospital and Medical Center in Englewood, New Jersey, recently published a paper on experience in their clinic, where they compared costs among nonstandardized dose-rounding practices, standardized dose-rounding practices, and theoretical exact dosing for infliximab.
Read more about biosimilar infliximab.
The researchers performed a retrospective chart review from October 2016 to March 2017, and included patients receiving infliximab for inflammatory bowel disease in the center’s outpatient infusion clinic. A total of 69 patients received nonstandardized dose rounding, and 45 patients received standardized dose rounding (using a chart with specified measures), during this period.
The nonstandardized group was treated with a total of 773 vials over an approximate 3-month period. Had this group been treated using the standardized dose-rounding chart, the authors estimate that 40 vials of infliximab could have been saved, producing a cost savings of $44,472. If the savings were consistent over a year, assuming that 40 patients receive infliximab each month, using the standardized chart could produce a cost savings of $104,640 per year at the center.
Using standardization in dose rounding led to slightly longer time from weight measurement to order verification, but the minor difference in time was, the investigators said, not practically meaningful. Greater experience with standardized rounding could also reduce the time to order verification.
The authors concluded that dose rounding helped the center to avoid unnecessary costs, and that using a standard method could help to improve pharmacy workflow.
Reference
Park JJ, Boutillier L, Cruz JE, Joung G, Nemeth J. Effect of standardized infliximab dose rounding on an outpatient infusion center. J Manag Care Spec Pharm. 2018;24(10):1028-1033. doi: 10.18553/jmcp.2018.24.10.1028.
Competitive Pricing in Biosimilars: How Adalimumab Could Shape the Industry
Published: October 29th 2024 | Updated: October 29th 2024Sophia Humphreys, PharmD, MHA, BCBBS, of Sutter Health notes that although initial adoption of adalimumab biosimilars remained low in 2023, competitive pricing pressures have already benefited patients and the health care sector.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Sandoz Report: A Unified Approach to Overcoming Drug Shortages
October 10th 2024A report from Sandoz emphasizes the need for collaboration among stakeholders to eliminate drug shortages impacting over 90% of hospital systems in the US, recommending policy changes and actions to address the ongoing issue, which has caused treatment delays and increased costs.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
AAM Report: Despite Massive Savings, Patient OOP Costs on Biosimilars, Generics Remain High, Part 2
September 24th 2024Part 2 of our series diving into the Association for Accessible Medicines' (AAM) latest report discusses that while generics and biosimilars saved $445 billion in 2023, their potential is hindered by high patient costs, drug shortages, and ineffective policies, underscoring the need for reforms to fully realize their benefits.
AAM Report: Generics and Biosimilars Savings Reach $445 Billion in 2023, Part 1
September 18th 2024Savings from generic and biosimilar drugs totaled $445 billion in 2023, showing promise for the growth of both markets and highlighting the success of expansion policies for these products, according to a new report from the Association for Accessible Medicines (AAM).